(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Entera Bio Ltd., Veeva Systems, and Future FinTech Group.

The three biggest losers today are Greenrose Acquisition Corp., Greenrose Acquisition Corp., and Okta.

Winners today

1. Entera Bio Ltd. (ENTXW) – 242.67%

NASDAQ ended the session with Entera Bio Ltd. jumping 242.67% to $0.03 on Thursday, after five consecutive sessions in a row of losses. NASDAQ jumped 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.

Yearly Top and Bottom Value

Entera Bio Ltd.’s stock is valued at $0.03 at 17:32 EST, way higher than its 52-week high of $0.03.

More news about Entera Bio Ltd..

2. Veeva Systems (VEEV) – 20.25%

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and data solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services that include outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

NYSE ended the session with Veeva Systems jumping 20.25% to $199.25 on Thursday while NYSE jumped 0.97% to $15,031.08.

Earnings Per Share

As for profitability, Veeva Systems has a trailing twelve months EPS of $3.01.

PE Ratio

Veeva Systems has a trailing twelve months price to earnings ratio of 66.2. Meaning, the purchaser of the share is investing $66.2 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.72%.

Volatility

Veeva Systems’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.25%, a negative 0.37%, and a positive 1.38%.

Veeva Systems’s highest amplitude of average volatility was 1.36% (last week), 1.15% (last month), and 1.38% (last quarter).

Moving Average

Veeva Systems’s worth is way above its 50-day moving average of $176.66 and way higher than its 200-day moving average of $176.59.

Previous days news about Veeva Systems

• Veeva systems (veev) extends tie-up with lotus clinical. According to Zacks on Wednesday, 31 May, "Veeva Systems Inc. (VEEV Quick QuoteVEEV – Free Report) announced that Lotus Clinical Research expanded its partnership with Veeva Systems and broadened the adoption of the Veeva Vault Clinical Suite. ", "This month, Veeva Systems announced that Minaris Regenerative Medicine selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations. "

More news about Veeva Systems.

3. Future FinTech Group (FTFT) – 16.94%

Future FinTech Group Inc., through its subsidiaries, operates a real-name block chain e-commerce platform that integrates block chain and internet technology in People's Republic of China. It operates through CCM Shopping Mall Membership, Sales of Goods, and Others segments. The company offers Chain Cloud Mall (CCM), an enterprise customer interactive and comprehensive shopping and sales service platform; NONOGIRL, a cross-border e-commerce platform; and DCON, a block chain-based application incubator and a digital payment system. It also engages in the development of block chain-based e-commerce and financial technology; and provides technical services and support for real name and blockchain based assets. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Future FinTech Group jumping 16.94% to $1.44 on Thursday, following the last session’s upward trend. NASDAQ jumped 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, Future FinTech Group has a trailing twelve months EPS of $-0.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.41%.

More news about Future FinTech Group.

4. Esports Entertainment Group (GMBLW) – 16.86%

NASDAQ ended the session with Esports Entertainment Group rising 16.86% to $0.03 on Thursday, after five consecutive sessions in a row of losses. NASDAQ rose 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around positive trend trading session today.

Yearly Top and Bottom Value

Esports Entertainment Group’s stock is valued at $0.03 at 17:32 EST, above its 52-week high of $0.03.

More news about Esports Entertainment Group.

5. iRobot (IRBT) – 10.04%

iRobot Corporation designs, builds, and sells robots and home innovation products in the United States, Europe, the Middle East, Africa, Japan, and internationally. The company offers floor care products, including Roomba floor vacuuming robots; Roomba accessories and consumables, such as the Clean Base Automatic Dirt Disposal, replacement dirt disposal bags for the Clean Base, filters, brushes, and batteries; Braava family of automatic floor mopping robots; and Braava accessories and consumables, which include cleaning solution, washable and disposable mopping pads, replacement tanks, and batteries, as well as subscription services. It also provides H1 Handheld Vacuum, a portable vacuum; H1 Handheld Vacuum accessories comprising filters, chargers, batteries, and an extension kit that converts the H1 Handheld Vacuum into a stick vacuum; air purifiers under the Aeris brand; Root robots to help children learn how to code; and Create 3, a mobile robot platform that offers an opportunity for educators, developers, and high-school and college students to program behaviors, sounds, movements, and add additional electronics, as well as sells filters and fabric covers. The company sells its products through chain stores and other national retailers, distributors, and resellers, as well as through its website and app, and e-commerce websites. iRobot Corporation was incorporated in 1990 and is headquartered in Bedford, Massachusetts.

NASDAQ ended the session with iRobot rising 10.04% to $39.01 on Thursday while NASDAQ rose 1.28% to $13,100.98.

Earnings Per Share

As for profitability, iRobot has a trailing twelve months EPS of $-12.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -61.8%.

Volume

Today’s last reported volume for iRobot is 864740 which is 124.61% above its average volume of 384982.

Yearly Top and Bottom Value

iRobot’s stock is valued at $39.01 at 17:32 EST, way under its 52-week high of $60.25 and way above its 52-week low of $31.37.

Sales Growth

iRobot’s sales growth is negative 11% for the ongoing quarter and negative 3.7% for the next.

Volatility

iRobot’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.55%, a negative 0.46%, and a positive 1.30%.

iRobot’s highest amplitude of average volatility was 2.20% (last week), 1.93% (last month), and 1.30% (last quarter).

More news about iRobot.

6. Match Group (MTCH) – 9.54%

Match Group, Inc. provides dating products worldwide. The company's portfolio of brands includes Tinder, Match, The League, Azar, Meetic, OkCupid, Hinge, Pairs, PlentyOfFish, and Hakuna, as well as a various other brands. The company was incorporated in 1986 and is based in Dallas, Texas.

NASDAQ ended the session with Match Group jumping 9.54% to $37.79 on Thursday while NASDAQ jumped 1.28% to $13,100.98.

Earnings Per Share

As for profitability, Match Group has a trailing twelve months EPS of $1.07.

PE Ratio

Match Group has a trailing twelve months price to earnings ratio of 35.32. Meaning, the purchaser of the share is investing $35.32 for every dollar of annual earnings.

More news about Match Group.

7. Erytech Pharma S.A. (ERYP) – 9.02%

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.

NASDAQ ended the session with Erytech Pharma S.A. rising 9.02% to $0.94 on Thursday while NASDAQ rose 1.28% to $13,100.98.

Earnings Per Share

As for profitability, Erytech Pharma S.A. has a trailing twelve months EPS of $-0.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.98%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Erytech Pharma S.A.’s EBITDA is -13.4.

More news about Erytech Pharma S.A..

8. Peloton (PTON) – 9%

Peloton Interactive, Inc. operates interactive fitness platform in North America and internationally. The company offers connected fitness products with touchscreen that streams live and on-demand classes under the Peloton Bike, Peloton Bike+, Peloton Tread, and Peloton Tread+ names. It also provides connected fitness subscriptions for various household users, and access to various live and on-demand classes, as well as Peloton Digital app for connected fitness subscribers to provide access to its classes. As of June 30, 2022, it had approximately 6.9 million members. The company markets and sells its interactive fitness products directly through its retail showrooms and at onepeloton.com. Peloton Interactive, Inc. was founded in 2012 and is headquartered in New York, New York.

NASDAQ ended the session with Peloton jumping 9% to $7.93 on Thursday, after two sequential sessions in a row of gains. NASDAQ jumped 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Peloton has a trailing twelve months EPS of $-6.84.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -279.85%.

Sales Growth

Peloton’s sales growth is negative 5.8% for the ongoing quarter and 6% for the next.

Moving Average

Peloton’s value is way below its 50-day moving average of $9.02 and way under its 200-day moving average of $10.31.

More news about Peloton.

9. GDS Holdings Limited (GDS) – 8.81%

GDS Holdings Limited, together with its subsidiaries, develops and operates data centers in the People's Republic of China. The company provides colocation, managed hosting, and managed cloud services, as well as consulting services to the cloud, internet and banking industries. The company serves cloud service providers, Internet companies, financial institutions, telecommunications and IT service providers, and large domestic private sector and multinational corporations. The company has a strategic partnership with GIC Private Limited to develop and operate hyperscale build-to-suit data centers in China. GDS Holdings Limited was founded in 2001 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with GDS Holdings Limited rising 8.81% to $10.62 on Thursday while NASDAQ jumped 1.28% to $13,100.98.

Earnings Per Share

As for profitability, GDS Holdings Limited has a trailing twelve months EPS of $-1.16.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.6%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is 9.7% and a drop 7.1% for the next.

More news about GDS Holdings Limited.

10. Genprex (GNPX) – 8.45%

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

NASDAQ ended the session with Genprex rising 8.45% to $0.93 on Thursday, following the last session’s upward trend. NASDAQ rose 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Genprex has a trailing twelve months EPS of $-0.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 9.1% and positive 7.7% for the next.

More news about Genprex.

Losers Today

1. Greenrose Acquisition Corp. (GNRSW) – -55.17%

NASDAQ ended the session with Greenrose Acquisition Corp. falling 55.17% to $0.01 on Thursday, after five successive sessions in a row of losses. NASDAQ rose 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around up trend trading session today.

Yearly Top and Bottom Value

Greenrose Acquisition Corp.’s stock is valued at $0.01 at 17:32 EST, way above its 52-week high of $0.01.

More news about Greenrose Acquisition Corp..

2. Greenrose Acquisition Corp. (GNRS) – -48.57%

Greenrose Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2019 and is based in Amityville, New York.

NASDAQ ended the session with Greenrose Acquisition Corp. sliding 48.57% to $0.18 on Thursday, after five sequential sessions in a row of losses. NASDAQ rose 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Greenrose Acquisition Corp. has a trailing twelve months EPS of $-0.08.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 346.23%.

More news about Greenrose Acquisition Corp..

3. Okta (OKTA) – -16.99%

Okta, Inc. provides identity solutions for enterprises, small and medium-sized businesses, universities, non-profits, and government agencies in the United States and internationally. The company offers Okta's, a suite of products and services is used to manage and secure identities, such as Universal Directory, a cloud-based system of record to store and secure user, application, and device profiles for an organization; Single Sign-On that enables users to access applications in the cloud or on-premise from various devices; Adaptive Multi-Factor Authentication provides a layer of security for cloud, mobile, Web applications, and data; Lifecycle Management that enables IT organizations or developers to manage a user's identity throughout its lifecycle; API Access Management that enables organizations to secure APIs; Access Gateway enables organizations to extend the Workforce Identity Cloud; Advanced Server Access to manage and secure cloud infrastructure; and Okta Identity Governance, an identity access management and identity governance solutions. It also provides Universal Login allows customers to provide login experience across different applications and devices; Attack Protection, a suite of security capabilities that protect from malicious traffics; Adaptive Multi-Factor Authentication that minimizes friction to end users; Passwordless authentication enables users to login without a password and supports in various login methods; Machine to Machine provides standards-based authentication and authorization; Private Cloud that allows customers to run a dedicated cloud instance of Customer Identity Cloud; In addition, the company provides organization; Actions and Extensibility; and Enterprise Connections. It sells its products directly to customers through sales force and channel partners. The company was formerly known as Saasure, Inc. Okta, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

NASDAQ ended the session with Okta falling 16.99% to $75.46 on Thursday, after three consecutive sessions in a row of gains. NASDAQ jumped 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Okta has a trailing twelve months EPS of $-5.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.31%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Okta’s EBITDA is -97.08.

Yearly Top and Bottom Value

Okta’s stock is valued at $75.46 at 17:32 EST, way below its 52-week high of $111.35 and way above its 52-week low of $44.12.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Okta’s stock is considered to be oversold (<=20).

More news about Okta.

4. Castle Biosciences (CSTL) – -11.91%

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

NASDAQ ended the session with Castle Biosciences dropping 11.91% to $21.52 on Thursday, after two successive sessions in a row of losses. NASDAQ rose 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.65.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.33%.

Yearly Top and Bottom Value

Castle Biosciences’s stock is valued at $21.52 at 17:32 EST, way under its 52-week high of $36.10 and way higher than its 52-week low of $15.58.

Moving Average

Castle Biosciences’s worth is below its 50-day moving average of $22.97 and way below its 200-day moving average of $24.60.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Castle Biosciences’s EBITDA is 2.42.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Castle Biosciences’s stock is considered to be overbought (>=80).

More news about Castle Biosciences.

5. Precision BioSciences (DTIL) – -11.9%

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; and iECURE to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

NASDAQ ended the session with Precision BioSciences dropping 11.9% to $0.74 on Thursday while NASDAQ rose 1.28% to $13,100.98.

Earnings Per Share

As for profitability, Precision BioSciences has a trailing twelve months EPS of $-1.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -197.62%.

Sales Growth

Precision BioSciences’s sales growth is 67.8% for the present quarter and 20.3% for the next.

Yearly Top and Bottom Value

Precision BioSciences’s stock is valued at $0.74 at 17:32 EST, way below its 52-week high of $2.21 and above its 52-week low of $0.68.

More news about Precision BioSciences.

6. Evelo Biosciences (EVLO) – -7.77%

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Evelo Biosciences falling 7.77% to $0.14 on Thursday, after two sequential sessions in a row of losses. NASDAQ rose 1.28% to $13,100.98, following the last session’s downward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Evelo Biosciences has a trailing twelve months EPS of $-1.12.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 57.5% and 39.3%, respectively.

Volume

Today’s last reported volume for Evelo Biosciences is 656964 which is 82.57% below its average volume of 3770440.

More news about Evelo Biosciences.

7. Foresight Autonomous Holdings Ltd. (FRSX) – -7.39%

Foresight Autonomous Holdings Ltd., a technology company, engages in the design, development, and commercialization of sensor systems for the automotive industry in Israel and China. It develops in-line-of-sight vision systems and beyond-line-of-site cellular-based applications. The company offers QuadSight system, a quad-camera multi-spectral vision system for the semi-autonomous and autonomous vehicle market; V2X (vehicle-to-everything), an accident prevention solution based on real-time multi-agents positioning algorithms that enables communication between vehicles, infrastructure, grid, home, and network; and Eye-Net Protect, a cellular-based V2X solution that provides real-time pre-collision alerts to vulnerable road users, such as pedestrians, cyclists, scooter drivers, etc. by using smartphones. It has a strategic cooperation agreement with FLIR Systems, Inc. to develop, market, and distribute QuadSight vision system. The company was formerly known as Asia Development (A.D.B.M.) Ltd. and changed its name to Foresight Autonomous Holdings Ltd. in 2016. Foresight Autonomous Holdings Ltd. was incorporated in 1977 and is headquartered in Ness Ziona, Israel.

NASDAQ ended the session with Foresight Autonomous Holdings Ltd. dropping 7.39% to $2.11 on Thursday while NASDAQ jumped 1.28% to $13,100.98.

Earnings Per Share

As for profitability, Foresight Autonomous Holdings Ltd. has a trailing twelve months EPS of $-2.46.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -56%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Foresight Autonomous Holdings Ltd.’s EBITDA is -0.52.

Volume

Today’s last reported volume for Foresight Autonomous Holdings Ltd. is 23407 which is 59.39% below its average volume of 57652.

More news about Foresight Autonomous Holdings Ltd..

8. EHang Holdings Limited (EH) – -6.97%

EHang Holdings Limited operates as an autonomous aerial vehicle (AAV) technology platform company in the People's Republic of China, North America, East Asia, Europe, West Asia, and internationally. It designs, develops, manufactures, sells, and operates AAVs, as well as their supporting systems and infrastructure for a range of industries and applications, including passenger transportation, logistics, smart city management, and aerial media solutions. EHang Holdings Limited has a strategic partnership with Shenzhen Expressway Operation Development Company Limited. The company was incorporated in 2014 and is headquartered in Guangzhou, the People's Republic of China.

NASDAQ ended the session with EHang Holdings Limited dropping 6.97% to $10.01 on Thursday while NASDAQ jumped 1.28% to $13,100.98.

Earnings Per Share

As for profitability, EHang Holdings Limited has a trailing twelve months EPS of $-0.81.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -122.26%.

Yearly Top and Bottom Value

EHang Holdings Limited’s stock is valued at $10.01 at 17:32 EST, way under its 52-week high of $17.84 and way higher than its 52-week low of $3.32.

Moving Average

EHang Holdings Limited’s value is below its 50-day moving average of $10.70 and way higher than its 200-day moving average of $8.52.

More news about EHang Holdings Limited.

9. DZS (DZSI) – -6.26%

DZS Inc. provides network access solutions and communications platforms for service provider and enterprise networks in the Americas, Europe, the Middle East, Africa, and Asia. It offers mobile transport products, including standard Ethernet/IP or multiprotocol label switching interfaces and interoperate to mobile operators that enables them to upgrade their mobile fronthaul/backhaul systems and migrate to 5G and beyond; broadband access products, which consists of switching and routing products to carriers and service providers to connect residential and business customers; and connected premises products, comprising of indoor/outdoor optical network terminal gateways. The company also provides software and services, which consists of software defined networking orchestration solutions, network function virtualization, and professional and technical support services. It has a strategic partnership with Quanta Cloud Technology; and Plume Design, Inc. The company was formerly known as DASAN Zhone Solutions, Inc. and changed its name to DZS Inc. in August 2020. The company was founded in 1996 and is based in Plano, Texas.

NASDAQ ended the session with DZS falling 6.26% to $5.99 on Thursday while NASDAQ jumped 1.28% to $13,100.98.

Earnings Per Share

As for profitability, DZS has a trailing twelve months EPS of $-1.71.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.81%.

Moving Average

DZS’s worth is way under its 50-day moving average of $7.10 and way below its 200-day moving average of $11.01.

Yearly Top and Bottom Value

DZS’s stock is valued at $5.99 at 17:32 EST, way under its 52-week high of $19.66 and higher than its 52-week low of $5.95.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 200% and 320%, respectively.

More news about DZS.

10. Evogene Ltd Ordinary shares (EVGN) – -6.22%

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

NASDAQ ended the session with Evogene Ltd Ordinary shares dropping 6.22% to $0.60 on Thursday while NASDAQ rose 1.28% to $13,100.98.

Earnings Per Share

As for profitability, Evogene Ltd Ordinary shares has a trailing twelve months EPS of $-0.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.78%.

Volume

Today’s last reported volume for Evogene Ltd Ordinary shares is 135948 which is 84.9% above its average volume of 73523.

Yearly Top and Bottom Value

Evogene Ltd Ordinary shares’s stock is valued at $0.60 at 17:32 EST, way below its 52-week high of $1.30 and higher than its 52-week low of $0.55.

Revenue Growth

Year-on-year quarterly revenue growth grew by 112.2%, now sitting on 1.68M for the twelve trailing months.

More news about Evogene Ltd Ordinary shares.

Stay up to date with our winners and losers daily report